Literature DB >> 22580121

Predicting pneumonitis risk: a dosimetric alternative to mean lung dose.

Susan L Tucker1, Radhe Mohan, Raweewan Liengsawangwong, Mary K Martel, Zhongxing Liao.   

Abstract

PURPOSE: To determine whether the association between mean lung dose (MLD) and risk of severe (grade ≥3) radiation pneumonitis (RP) depends on the dose distribution pattern to normal lung among patients receiving 3-dimensional conformal radiation therapy for non-small-cell lung cancer. METHODS AND MATERIALS: Three cohorts treated with different beam arrangements were identified. One cohort (2-field boost [2FB]) received 2 parallel-opposed (anteroposterior-posteroanterior) fields per fraction initially, followed by a sequential boost delivered using 2 oblique beams. The other 2 cohorts received 3 or 4 straight fields (3FS and 4FS, respectively), ie, all fields were irradiated every day. The incidence of severe RP was plotted against MLD in each cohort, and data were analyzed using the Lyman-Kutcher-Burman (LKB) model.
RESULTS: The incidence of grade ≥3 RP rose more steeply as a function of MLD in the 2FB cohort (N=120) than in the 4FS cohort (N=138), with an intermediate slope for the 3FS group (N=99). The estimated volume parameter from the LKB model was n=0.41 (95% confidence interval, 0.15-1.0) and led to a significant improvement in fit (P=.05) compared to a fit with volume parameter fixed at n=1 (the MLD model). Unlike the MLD model, the LKB model with n=0.41 provided a consistent description of the risk of severe RP in all three cohorts (2FB, 3FS, 4FS) simultaneously.
CONCLUSIONS: When predicting risk of grade ≥3 RP, the mean lung dose does not adequately take into account the effects of high doses. Instead, the effective dose, computed from the LKB model using volume parameter n=0.41, may provide a better dosimetric parameter for predicting RP risk. If confirmed, these findings support the conclusion that for the same MLD, high doses to small lung volumes ("a lot to a little") are worse than low doses to large volumes ("a little to a lot").
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22580121     DOI: 10.1016/j.ijrobp.2012.03.052

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.

Authors:  Zhongxing Liao; J Jack Lee; Ritsuko Komaki; Daniel R Gomez; Michael S O'Reilly; Frank V Fossella; George R Blumenschein; John V Heymach; Ara A Vaporciyan; Stephen G Swisher; Pamela K Allen; Noah Chan Choi; Thomas F DeLaney; Stephen M Hahn; James D Cox; Charles S Lu; Radhe Mohan
Journal:  J Clin Oncol       Date:  2018-01-02       Impact factor: 44.544

2.  Non-coplanar VMAT combined with non-uniform dose prescription markedly reduces lung dose in breath-hold lung SBRT.

Authors:  Jens Fleckenstein; Judit Boda-Heggemann; Kerstin Siebenlist; Tanya Gudzheva; Natallia Prakofyeva; Frank Lohr; Frederik Wenz; Anna Simeonova-Chergou
Journal:  Strahlenther Onkol       Date:  2018-05-25       Impact factor: 3.621

3.  The mean lung dose (MLD) : predictive criterion for lung damage?

Authors:  Thomas Herrmann; Peter Geyer; Steffen Appold
Journal:  Strahlenther Onkol       Date:  2015-04-13       Impact factor: 3.621

4.  Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy.

Authors:  Xin Shelley Wang; Qiuling Shi; Loretta A Williams; Ritsuko Komaki; Daniel R Gomez; Steven H Lin; Joe Y Chang; Michael S O'Reilly; Raza H Bokhari; James D Cox; Radhe Mohan; Charles S Cleeland; Zhongxing Liao
Journal:  J Pain Symptom Manage       Date:  2016-02-16       Impact factor: 3.612

Review 5.  Proton therapy for locally advanced non-small cell lung cancer.

Authors:  Olsi Gjyshi; Zhongxing Liao
Journal:  Br J Radiol       Date:  2019-08-20       Impact factor: 3.039

Review 6.  Nondosimetric risk factors for radiation-induced lung toxicity.

Authors:  Feng-Ming Spring Kong; Shulian Wang
Journal:  Semin Radiat Oncol       Date:  2014-12-15       Impact factor: 5.934

7.  Perspectives on the model-based approach to proton therapy trials: A retrospective study of a lung cancer randomized trial.

Authors:  Aimee L McNamara; David C Hall; Nadya Shusharina; Amy Liu; Xiong Wei; Ali Ajdari; Radhe Mohan; Zhongxing Liao; Harald Paganetti
Journal:  Radiother Oncol       Date:  2020-03-27       Impact factor: 6.280

8.  Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer.

Authors:  Ane L Appelt; Søren M Bentzen; Anders Jakobsen; Ivan R Vogelius
Journal:  Acta Oncol       Date:  2014-06-30       Impact factor: 4.089

9.  Dosimetric and Radiobiological Comparison of External Beam Radiotherapy Using Simultaneous Integrated Boost Technique for Esophageal Cancer in Different Location.

Authors:  Lu Wang; Chengqiang Li; Xue Meng; Chengming Li; Xindong Sun; Dongping Shang; Linlin Pang; Yixiao Li; Jie Lu; Jinming Yu
Journal:  Front Oncol       Date:  2019-07-25       Impact factor: 6.244

10.  Correlation of normal lung density changes with dose after stereotactic body radiotherapy (SBRT) for early stage lung cancer.

Authors:  Karine A Al Feghali; Qixue Charles Wu; Suneetha Devpura; Chang Liu; Ahmed I Ghanem; Ning Winston Wen; Munther Ajlouni; Michael J Simoff; Benjamin Movsas; Indrin J Chetty
Journal:  Clin Transl Radiat Oncol       Date:  2020-02-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.